PediatricsNCT07035184
A Comparative Study Between Age-Based and Weight-Based Bupivacaine Dosing for Pediatric Spinal Anesthesia in Children Undergoing Elective Infra-Umbilical Surgeries
A study testing Spinal Anesthesia with Bupivacaine in people with Pediatrics and Spinal Aneshtesia, run by Cairo University at 1 site in Egypt.
Trial summary
This prospective randomized double-blinded controlled trial will include 60 pediatric patients aged 1 - 6 years old, both sexes, with American society of anesthesiologists (I and II) and undergoing elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes. Read more about this study
- Who is it for?
- Ages 1 year to 6 years
- Conditions the study is for
- Pediatrics, Spinal Aneshtesia, Infraumbilical Surgeries
- What is being tested?
- Spinal Anesthesia with Bupivacaine
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2025to 15 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 6 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged 1-6 years
- Both genders.
- American Society of Anesthesiologists (ASA) physical status I or II.
- Elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes.
Who cannot join
- Guardian refusal.
- Children with significant congenital heart disease (e.g., septal defects requiring surgical intervention)
- Children with neuromuscular disorders or high intracranial pressure.
- Children with spinal deformities or morbid obesity (body mass index (BMI) above the 99th percentile).
- Children with a history or family history of coagulation disorders.
- Children with local infection at the site of skin puncture for spinal anesthesia.
Show all 9Show fewer
- Children with known allergy to Bupivacaine.
- Surgeries requiring Trendelenburg or prone position.
- Unexpected prolongation of surgery > 90 minutes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hany M.EH Mohammed, MD contact
Egypt1 site
Abu Elreesh Pediatric Hospital
Cairo, Assida Zainab, 12211
Hany M. El-Hadi Mohammed, MD, +201003066806, oblfollower_2001@yahoo.com, hany.elhadi@kasralainy.edu.eg
About this study
Official title: A Comparative Study Between Age-Based and Weight-Based Bupivacaine Dosing for Pediatric Spinal Anesthesia in Children Undergoing Elective Infra-Umbilical Surgeries: A Randomized Double-Blinded Controlled Trial
This prospective randomized double-blinded controlled trial will include 60 pediatric patients aged 1 - 6 years old, both sexes, with American society of anesthesiologists (I and II) and undergoing elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes. Patients will be randomly divided into two equal groups: Weight-based dosing (Group A) and age-based dosing group (Group B). Both groups will receive hyperbaric bupivacaine 0.5%. The aim of the study is to evaluate the effectiveness of using age based dosing of Bupivacaine compared with standard method of weight based dosing in pediatric spinal anesthesia.
Read the detailed description
This prospective randomized double-blinded controlled trial will be conducted on 60 pediatric patients who will undergo elective infra-umbilical surgeries, e.g., inguinal hernia repair, orchiopexy, etc. admitted to the operating theatres of Abu El Reesh Children's Hospital, Cairo University.
Randomization and blinding An online randomization program (http://www.randomizer.org) will be used to generate a random list, and each patient's code will be kept in an opaque sealed envelope. Patients will be randomly allocated in a 1:1 allocation ratio into two equal groups in a parallel manner:
- Group A (n=30): Children will receive spinal anesthesia according to weight-based dosing calculation of bupivacaine
- Group B (n=30): Children will receive spinal anesthesia according to age-based dosing calculation of bupivacaine. The patient and/or related guardian will be blinded to group assignment as well as the anesthesiologist involved in data collection and analysis. A physician who is not involved in the study prepared the interventional medications.
Methods:
All patients will be subjected to the followings:
- History taking and demographic data collection (age, sex, weight, and ASA).
- Complete clinical examination.
- Routine Laboratory investigations
All patients will be instructed to fast according to the following guidelines:
2 hours for clear fluids, 4 hours for breastmilk, 6 hours for formula milk and other particulate fluids. EMLA cream (5%) will be applied to the anticipated puncture sites for IV cannulation and covered for 45 minutes before transport to the OR, to facilitate the insertion of an intravenous (IV) cannula. Premedication included intramuscular (IM) midazolam at 0.3 mg/kg and atropine at 0.02 mg/kg, administered 15 minutes before transportation to the operating room (OR). Upon arrival in the OR, standard monitoring equipment will be applied, including electrocardiography, non-invasive blood pressure, and pulse oximetry. The anesthesia machine and all necessary equipment and medications for general anesthesia (GA) will be prepared for each patient. The IV cannula will be inserted, secured and checked with a saline flush. IV midazolam at a dose of 0.1 mg/kg will be given at the time of spinal anesthesia administration to ensure immobility during the procedure.
A Pediatric Analog Sedation Score (PASS) will be used to evaluate sedation levels during the procedure as well as intraoperatively, where a score of 0 = no sedation, 1 = slightly sedated, 2 = moderately sedated, 3 = well sedated, and 4 = heavily sedated. The target sedation score is 1, indicating minimal sedation. The child will be positioned in the lateral decubitus position, and under strict aseptic conditions, the lumbar region will be sterilized using Betadine. A lumbar puncture will be performed at the L4-L5 interspace (Tuffier's line) using a 2.5-inch 22-gauge Quincke needle by an experienced anesthesiologist. A formula will be used to estimate the distance from skin to subarachnoid space (mm) = [2 × weight (kg)]+ 7(mm). This will be used as a guide to reduce chances of inserting the spinal needle too deep. Two attempts at obtaining a free flow of cerebrospinal fluid (CSF) will be allowed; if unsuccessful, the patient will be excluded from the study and switched to GA. A new attempt involves removing the needle and reinserting it. The calculated dose of hyperbaric bupivacaine 0.5% (Trade name: Sunnypivacaine, Manufacturer: Sunny Pharmaceuticals, Country: Egypt) will be aspirated and administered via a 3-ml syringe.
Group A:
Hyperbaric bupivacaine 0.5% will be administered based on weight:
- 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg
- 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg.
Group B:
Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older.
After obtaining free flow of CSF, and negative aspiration test for blood, the local anesthetic will be administered slowly. Then, the child will be placed in a supine position with a small pillow under the head. IV fluids will be administered at a rate of 4 ml/kg/hr. Sensory and motor levels will be assessed every minute for the first 5 minutes. The adequacy of the block will be determined by the lack of response to a firm skin pinch at the dermatomal level. The peak sensory level will be determined when the dermatomal level remained unchanged in at least two consecutive assessments. If the patient reported pain, the block will be considered failed, and they are excluded from the study. Motor blockade at or above the L1 level will be tested using superficial abdominal reflexes. After a maximum of ten minutes after spinal anesthesia, the target peak sensory level should be at least T10, and the Bromage score should be 3, indicating a complete motor block. Only then the surgery will be proceeded. Iff inadequate sensory or motor block are observed (e.g., peak sensory level below T10 or Bromage score <3), GA will be administered, and the failure will be documented.
- Conditions
- Pediatrics, Spinal Aneshtesia, Infraumbilical Surgeries
- Being tested
- Spinal Anesthesia with Bupivacaine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spinal Anesthesia with BupivacaineProcedure or surgery
Group A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine.
Spinal Anesthesia with BupivacaineProcedure or surgery
Group B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine.
| Study group | Role | What they receive |
|---|---|---|
| Group A: weight-based formula group | Active comparator | Children will receive spinal anesthesia according to the weight-based dosing calculation of Hyperbaric bupivacaine 0.5% as following: 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg or 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg Receives: Procedure: Spinal Anesthesia with Bupivacaine |
| Group B: Age-based formula group | Active comparator | Children will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine. Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older. Receives: Procedure: Spinal Anesthesia with Bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
The peak sensory level
The peak sensory level will be assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch.
Measured: Assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch up to 30 minutes after subarachnoid block
Secondary outcomes (7)
Time of completion of spinal block
Time in seconds to complete block administration starting at the time of application of Betadine on the site of lumbar puncture to the time at which the patient is placed on their back after administration of spinal anesthesia
Measured: starts immediately at the time of application of Betadine on the site of lumbar puncture to the time at which the patient is placed on their back after immediately administering the spinal anesthesia
Duration of spinal block
Duration of block: the time in minutes from achieving peak sensory and motor level to the onset of pain or the movement of the legs.
Measured: starts immediately after achieving a peak sensory and motor levels and eds immediately by the onset of perioperative pain or movement of legs
Postoperative pain score
Postoperative pain score will be recorded using the Face, Legs, Activity, Cry, and Consolability (FLACC) Scale at 2, 4, and 6 hours from block administration. The scale consists of five categories: Face, Legs, Activity, Cry, and Consolability, each of which is scored from 0 to 2. A score of 0 represents no pain or distress, while a score of 2 indicates significant discomfort or distress.
Measured: Scale will be assessed postoperatively at 2 hours, 4 hours, and 6 hours from block administration.
The need for rescue analgesia in PACU
The need for rescue analgesia in PACU: IV Pethidine 1 mg/kg will be administered once for a pain score of 6 or higher using FLACC scale
Measured: Postoperatively at 2 hours after spinal block and up to 1 hour postoperatively
Incidence of failure of spinal block
Incidence of failure of spinal block defined by a failure to reach sensory level of T10 and modified Bromage score of 3; therefore, requiring the switch to GA.
Measured: 20 minutes after local anesthetic administration until 30 minutes after local anesthetic administration
Complications related to anesthesia
Complications related to anesthesia, such as vomiting, shivering, post dural puncture headache, and any manifestation suggestive of neurological injury, will be recorded.
Measured: started immediately after lumbar puncture and followed up for 2 hours postoperatively
Incidence of intraoperative complications
Incidence of hypotension and or bradycardia defined as and 20% decrease from baseline values
Measured: Started immediately after spinal block until the end of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Oct 2025 (estimated)
- Study completion15 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for PediatricsStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Mohammed El-Hadi Shoukat Mohammed, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07035184
- Sponsor's protocol ID
- "MS-503-2024"
- Status last verified
- Dec 2024
- First submitted
- 7 Jun 2025
- Last updated
- 25 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Only IPD used in the results publications
Publications
Crellin DJ, Harrison D, Santamaria N, Huque H, Babl FE. The Psychometric Properties of the FLACC Scale Used to Assess Procedural Pain. J Pain. 2018 Aug;19(8):862-872. doi: 10.1016/j.jpain.2018.02.013. Epub 2018 Mar 15.
PubMed 29551662Srinivasan P, Saravanan B, Kulandayan I, Thambidurai S, Mahalakshmi V. Evaluation of efficacy and safety of age-based intrathecal dosing of 0.5% hyperbaric bupivacaine in the paediatric age group. J Clin Diagn Res. 2020;14(8):29-31.
Troncin R, Dadure C. Paediatric spinal anaesthesia. management. 2009;4(3):8-12.
Elsharkawi NG. Simple pediatric analog sedation score (PASS). Anesth Analg. 1999 Jan;88(1):227. doi: 10.1097/00000539-199901000-00043. No abstract available.
PubMed 9895098Luca E, Schipa C, Cambise C, Sollazzi L, Aceto P. Implication of age-related changes on anesthesia management. Saudi J Anaesth. 2023 Oct-Dec;17(4):474-481. doi: 10.4103/sja.sja_579_23. Epub 2023 Aug 18.
PubMed 37779561Hebbes CP, Thompson JP. Pharmacokinetics of anaesthetic drugs at extremes of body weight. BJA Educ. 2018 Dec;18(12):364-370. doi: 10.1016/j.bjae.2018.09.001. Epub 2018 Oct 26. No abstract available.
PubMed 33456803Visavakul O, Leurcharusmee P, Pipanmekaporn T, Khorana J, Patumanond J, Phinyo P. Effective Dose Range of Intrathecal Isobaric Bupivacaine to Achieve T5-T10 Sensory Block Heights for Elderly and Overweight Patients: An Observational Study. Medicina (Kaunas). 2023 Mar 1;59(3):484. doi: 10.3390/medicina59030484.
PubMed 36984485Parthasarathy S, Senthilkumar T. Age-based Local Anesthetic Dosing in Pediatric Spinal Anesthesia: Evaluation of a New Formula - A Pilot Study in Indian Patients. Anesth Essays Res. 2017 Jul-Sep;11(3):627-629. doi: 10.4103/aer.AER_246_16.
PubMed 28928560Lonnqvist PA. Spinal anaesthesia in children: A narrative review. Best Pract Res Clin Anaesthesiol. 2023 Jun;37(2):133-138. doi: 10.1016/j.bpa.2023.01.002. Epub 2023 Feb 7.
PubMed 37321762Jefferson FA, Findlay BL, Handlogten KS, Gargollo PC, Warner LL, Woodbury JM, Haile DT, Granberg CF. Spinal anesthesia in infants undergoing urologic surgery duration greater than 60 minutes. J Pediatr Urol. 2022 Dec;18(6):786.e1-786.e7. doi: 10.1016/j.jpurol.2022.07.003. Epub 2022 Jul 14.
PubMed 35945145Verma D, Naithani U, Gokula C, Harsha. Spinal anesthesia in infants and children: A one year prospective audit. Anesth Essays Res. 2014 Sep-Dec;8(3):324-9. doi: 10.4103/0259-1162.143124.
PubMed 25886329Heydinger G, Tobias J, Veneziano G. Fundamentals and innovations in regional anaesthesia for infants and children. Anaesthesia. 2021 Jan;76 Suppl 1:74-88. doi: 10.1111/anae.15283.
PubMed 33426659
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study Between Age-Based and Weight-Based Bupivacaine Dosing for Pediatric Spinal Anesthesia in Children Undergoing Elective Infra-Umbilical Surgeries: A Randomized Double-Blinded Controlled Trial
- ClinicalTrials.gov ID
- NCT07035184
- Acronym / sponsor ID
- "MS-503-2024"
- Conditions
- Pediatrics, Spinal Aneshtesia, Infraumbilical Surgeries
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 15 Oct 2025 (estimated)
- First posted
- 25 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective randomized double-blinded controlled trial will include 60 pediatric patients aged 1 - 6 years old, both sexes, with American society of anesthesiologists (I and II) and undergoing elective infra-umbilical surgeries with anticipated duration ≤ 90 minutes. Patients will be randomly divided into two equal groups: Weight-based dosing (Group A) and age-based dosing group (Group B). Both groups will receive hyperbaric bupivacaine 0.5%. The aim of the study is to evaluate the effectiveness of using age based dosing of Bupivacaine compared with standard method of weight based dosing in pediatric spinal anesthesia.
Detailed description
This prospective randomized double-blinded controlled trial will be conducted on 60 pediatric patients who will undergo elective infra-umbilical surgeries, e.g., inguinal hernia repair, orchiopexy, etc. admitted to the operating theatres of Abu El Reesh Children's Hospital, Cairo University.
Randomization and blinding An online randomization program (http://www.randomizer.org) will be used to generate a random list, and each patient's code will be kept in an opaque sealed envelope. Patients will be randomly allocated in a 1:1 allocation ratio into two equal groups in a parallel manner:
- Group A (n=30): Children will receive spinal anesthesia according to weight-based dosing calculation of bupivacaine
- Group B (n=30): Children will receive spinal anesthesia according to age-based dosing calculation of bupivacaine. The patient and/or related guardian will be blinded to group assignment as well as the anesthesiologist involved in data collection and analysis. A physician who is not involved in the study prepared the interventional medications.
Methods:
All patients will be subjected to the followings:
- History taking and demographic data collection (age, sex, weight, and ASA).
- Complete clinical examination.
- Routine Laboratory investigations
All patients will be instructed to fast according to the following guidelines:
2 hours for clear fluids, 4 hours for breastmilk, 6 hours for formula milk and other particulate fluids. EMLA cream (5%) will be applied to the anticipated puncture sites for IV cannulation and covered for 45 minutes before transport to the OR, to facilitate the insertion of an intravenous (IV) cannula. Premedication included intramuscular (IM) midazolam at 0.3 mg/kg and atropine at 0.02 mg/kg, administered 15 minutes before transportation to the operating room (OR). Upon arrival in the OR, standard monitoring equipment will be applied, including electrocardiography, non-invasive blood pressure, and pulse oximetry. The anesthesia machine and all necessary equipment and medications for general anesthesia (GA) will be prepared for each patient. The IV cannula will be inserted, secured and checked with a saline flush. IV midazolam at a dose of 0.1 mg/kg will be given at the time of spinal anesthesia administration to ensure immobility during the procedure.
A Pediatric Analog Sedation Score (PASS) will be used to evaluate sedation levels during the procedure as well as intraoperatively, where a score of 0 = no sedation, 1 = slightly sedated, 2 = moderately sedated, 3 = well sedated, and 4 = heavily sedated. The target sedation score is 1, indicating minimal sedation. The child will be positioned in the lateral decubitus position, and under strict aseptic conditions, the lumbar region will be sterilized using Betadine. A lumbar puncture will be performed at the L4-L5 interspace (Tuffier's line) using a 2.5-inch 22-gauge Quincke needle by an experienced anesthesiologist. A formula will be used to estimate the distance from skin to subarachnoid space (mm) = [2 × weight (kg)]+ 7(mm). This will be used as a guide to reduce chances of inserting the spinal needle too deep. Two attempts at obtaining a free flow of cerebrospinal fluid (CSF) will be allowed; if unsuccessful, the patient will be excluded from the study and switched to GA. A new attempt involves removing the needle and reinserting it. The calculated dose of hyperbaric bupivacaine 0.5% (Trade name: Sunnypivacaine, Manufacturer: Sunny Pharmaceuticals, Country: Egypt) will be aspirated and administered via a 3-ml syringe.
Group A:
Hyperbaric bupivacaine 0.5% will be administered based on weight:
- 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg
- 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg.
Group B:
Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older.
After obtaining free flow of CSF, and negative aspiration test for blood, the local anesthetic will be administered slowly. Then, the child will be placed in a supine position with a small pillow under the head. IV fluids will be administered at a rate of 4 ml/kg/hr. Sensory and motor levels will be assessed every minute for the first 5 minutes. The adequacy of the block will be determined by the lack of response to a firm skin pinch at the dermatomal level. The peak sensory level will be determined when the dermatomal level remained unchanged in at least two consecutive assessments. If the patient reported pain, the block will be considered failed, and they are excluded from the study. Motor blockade at or above the L1 level will be tested using superficial abdominal reflexes. After a maximum of ten minutes after spinal anesthesia, the target peak sensory level should be at least T10, and the Bromage score should be 3, indicating a complete motor block. Only then the surgery will be proceeded. Iff inadequate sensory or motor block are observed (e.g., peak sensory level below T10 or Bromage score <3), GA will be administered, and the failure will be documented.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A: weight-based formula group | Active comparator | Procedure: Spinal Anesthesia with BupivacaineChildren will receive spinal anesthesia according to the weight-based dosing calculation of Hyperbaric bupivacaine 0.5% as following: 0.4 mg/kg (0.08 ml/kg) for children weighing 5-15 kg or 0.3 mg/kg (0.06 ml/kg) for children weighing >15 kg |
| Group B: Age-based formula group | Active comparator | Procedure: Spinal Anesthesia with BupivacaineChildren will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine. Hyperbaric bupivacaine 0.5% will be calculated using Partha formula by dividing the child's age in years by 5. The resultant figure will be considered to be the dose of Bupivacaine in ml. If the number of months after the completion of a year in age is more than 6 months, the child's age will be noted to be the year older. |
Who may qualify
- Ages
- 1 year to 6 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children aged 1-6 years
Key exclusion criteria (9 listed)
- Guardian refusal.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spinal Anesthesia with BupivacaineGroup A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine. | Procedure or surgery | Group A: weight-based formula group |
| Spinal Anesthesia with BupivacaineGroup B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine. | Procedure or surgery | Group B: Age-based formula group |
Primary outcome
The peak sensory level
Time frame: Assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch up to 30 minutes after subarachnoid block
The peak sensory level will be assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch.
7 secondary outcomes
Time of completion of spinal block
Time frame: starts immediately at the time of application of Betadine on the site of lumbar puncture to the time at which the patient is placed on their back after immediately administering the spinal anesthesia
Duration of spinal block
Time frame: starts immediately after achieving a peak sensory and motor levels and eds immediately by the onset of perioperative pain or movement of legs
Postoperative pain score
Time frame: Scale will be assessed postoperatively at 2 hours, 4 hours, and 6 hours from block administration.
The need for rescue analgesia in PACU
Time frame: Postoperatively at 2 hours after spinal block and up to 1 hour postoperatively
Incidence of failure of spinal block
Time frame: 20 minutes after local anesthetic administration until 30 minutes after local anesthetic administration
Complications related to anesthesia
Time frame: started immediately after lumbar puncture and followed up for 2 hours postoperatively
Incidence of intraoperative complications
Time frame: Started immediately after spinal block until the end of surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2025.
- Results publication: PubMed 29551662Crellin DJ, Harrison D, Santamaria N, Huque H, Babl FE. The Psychometric Properties of the FLACC Scale Used to Assess Procedural Pain. J Pain. 2018 Aug;19(8):862-872. doi: 10.1016/j.jpain.2018.02.013. Epub 2018 Mar 15.
- Results publicationSrinivasan P, Saravanan B, Kulandayan I, Thambidurai S, Mahalakshmi V. Evaluation of efficacy and safety of age-based intrathecal dosing of 0.5% hyperbaric bupivacaine in the paediatric age group. J Clin Diagn Res. 2020;14(8):29-31.
- Results publicationTroncin R, Dadure C. Paediatric spinal anaesthesia. management. 2009;4(3):8-12.
- Results publication: PubMed 9895098Elsharkawi NG. Simple pediatric analog sedation score (PASS). Anesth Analg. 1999 Jan;88(1):227. doi: 10.1097/00000539-199901000-00043. No abstract available.
- Results publication: PubMed 37779561Luca E, Schipa C, Cambise C, Sollazzi L, Aceto P. Implication of age-related changes on anesthesia management. Saudi J Anaesth. 2023 Oct-Dec;17(4):474-481. doi: 10.4103/sja.sja_579_23. Epub 2023 Aug 18.
- Results publication: PubMed 33456803Hebbes CP, Thompson JP. Pharmacokinetics of anaesthetic drugs at extremes of body weight. BJA Educ. 2018 Dec;18(12):364-370. doi: 10.1016/j.bjae.2018.09.001. Epub 2018 Oct 26. No abstract available.
- Results publication: PubMed 36984485Visavakul O, Leurcharusmee P, Pipanmekaporn T, Khorana J, Patumanond J, Phinyo P. Effective Dose Range of Intrathecal Isobaric Bupivacaine to Achieve T5-T10 Sensory Block Heights for Elderly and Overweight Patients: An Observational Study. Medicina (Kaunas). 2023 Mar 1;59(3):484. doi: 10.3390/medicina59030484.
- Results publication: PubMed 28928560Parthasarathy S, Senthilkumar T. Age-based Local Anesthetic Dosing in Pediatric Spinal Anesthesia: Evaluation of a New Formula - A Pilot Study in Indian Patients. Anesth Essays Res. 2017 Jul-Sep;11(3):627-629. doi: 10.4103/aer.AER_246_16.
- Results publication: PubMed 37321762Lonnqvist PA. Spinal anaesthesia in children: A narrative review. Best Pract Res Clin Anaesthesiol. 2023 Jun;37(2):133-138. doi: 10.1016/j.bpa.2023.01.002. Epub 2023 Feb 7.
- Results publication: PubMed 35945145Jefferson FA, Findlay BL, Handlogten KS, Gargollo PC, Warner LL, Woodbury JM, Haile DT, Granberg CF. Spinal anesthesia in infants undergoing urologic surgery duration greater than 60 minutes. J Pediatr Urol. 2022 Dec;18(6):786.e1-786.e7. doi: 10.1016/j.jpurol.2022.07.003. Epub 2022 Jul 14.
- Results publication: PubMed 25886329Verma D, Naithani U, Gokula C, Harsha. Spinal anesthesia in infants and children: A one year prospective audit. Anesth Essays Res. 2014 Sep-Dec;8(3):324-9. doi: 10.4103/0259-1162.143124.
- Results publication: PubMed 33426659Heydinger G, Tobias J, Veneziano G. Fundamentals and innovations in regional anaesthesia for infants and children. Anaesthesia. 2021 Jan;76 Suppl 1:74-88. doi: 10.1111/anae.15283.
- Individual participant dataSharing planned: Yes. Only IPD used in the results publications
Related trials for Pediatrics
Active, not recruitingPhase 2
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Optic Pathway Glioma
Not yet recruiting
Two Modalities of Ventilation on the Occurrence of Respiratory Complications During Inhalational Anaesthetic Induction in Children
Anaesthetic Induction, Respiratory Complications of Care
Recruiting
Smith Magenis Syndrome and Autism Spectrum Disorders
Smith-Magenis Syndrome, Autism Spectrum Disorder
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Active, not recruitingObservational study
A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Neuroblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hany M.EH Mohammed, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spinal Anesthesia with Bupivacaine in people with Pediatrics and Spinal Aneshtesia, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hany M.EH Mohammed, MD (+201003066806, oblfollower_2001@yahoo.com, hany.elhadi@kasralainy.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The peak sensory level (time frame: Assessed 5 minutes after intrathecal bupivacaine injection, and evaluated by a firm skin pinch up to 30 minutes after subarachnoid block). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07035184, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.